Patents by Inventor Rama K. Mishra

Rama K. Mishra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10851082
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: December 1, 2020
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Javier Izquierdo-Ferrer, Purav Vagadia, Matthew R. Clutter, Rama K. Mishra, Leonidas C. Platanias
  • Publication number: 20200069662
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
    Type: Application
    Filed: August 2, 2019
    Publication date: March 5, 2020
    Applicant: ANGION BIOMEDICA CORP.
    Inventors: Bijoy PANICKER, Rama K. MISHRA, Dong Sung LIM, Lambertus J.W.M. OEHLEN, Dawoon JUNG
  • Publication number: 20200039941
    Abstract: Provided herein are small molecule modulators of CXCR4 activity (e.g., agonists, antagonists, inverse agonists, partial agonists), and methods of use thereof (e.g., for the treatment of disease).
    Type: Application
    Filed: October 8, 2019
    Publication date: February 6, 2020
    Inventors: Gary E. Schiltz, Richard J. Miller, Rama K. Mishra
  • Patent number: 10435375
    Abstract: Provided herein are small molecule modulators of CXCR4 activity (e.g., agonists, antagonists, inverse agonists, partial agonists), and methods of use thereof (e.g., for the treatment of disease).
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 8, 2019
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Richard J. Miller, Rama K. Mishra
  • Patent number: 10414760
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: September 17, 2019
    Assignee: ANGION BIOMEDICA CORP.
    Inventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J. W. M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung
  • Publication number: 20190125731
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
    Type: Application
    Filed: December 18, 2018
    Publication date: May 2, 2019
    Applicant: ANGION BIOMEDICA CORP.
    Inventors: Bijoy PANICKER, Rama K. MISHRA, Dong Sung LIM, Lambertus J.W.M. OEHLEN, Dawoon JUNG
  • Publication number: 20190062281
    Abstract: Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.
    Type: Application
    Filed: August 31, 2018
    Publication date: February 28, 2019
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Rama K. Mishra, Huiying Han, Sarki A. Abdulkadir, Javier Izquierdo-Ferrer, Atul D. Jain
  • Patent number: 10195184
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
    Type: Grant
    Filed: March 19, 2017
    Date of Patent: February 5, 2019
    Assignee: ANGION BIOMEDICA CORP.
    Inventors: Bijoy Panicker, Rama K. Mishra, Dong Sung Lim, Lambertus J. W. M. Oehlen, Dawoon Jung
  • Patent number: 10093668
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 9, 2018
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Rama K. Mishra, Leonidas C. Platanias, Javier Izquierdo-Ferrer
  • Publication number: 20180244654
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Application
    Filed: May 3, 2018
    Publication date: August 30, 2018
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Javier Izquierdo-Ferrer, Purav Vagadia, Matthew R. Clutter, Rama K. Mishra, Leonidas C. Platanias
  • Publication number: 20180155295
    Abstract: Provided herein are small molecule modulators of CXCR4 activity (e.g., agonists, antagonists, inverse agonists, partial agonists), and methods of use thereof (e.g., for the treatment of disease).
    Type: Application
    Filed: May 5, 2016
    Publication date: June 7, 2018
    Inventors: Gary E. Schiltz, Richard J. Miller, Rama K. Mishra
  • Publication number: 20180148438
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.
    Type: Application
    Filed: November 29, 2016
    Publication date: May 31, 2018
    Applicant: Angion Biomedica Corp
    Inventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J.W.M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung
  • Publication number: 20180008581
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
    Type: Application
    Filed: March 19, 2017
    Publication date: January 11, 2018
    Applicant: ANGION BIOMEDICA CORP.
    Inventors: Bijoy PANICKER, Rama K. MISHRA, Dong Sung LIM, Lambertus J.W.M. OEHLEN, Dawoon JUNG
  • Publication number: 20170253581
    Abstract: Disclosed are substituted heterocycles compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 7, 2017
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Rama K. Mishra, Huiying Han, Sarki A. Abdulkadir
  • Publication number: 20170121326
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Application
    Filed: October 28, 2016
    Publication date: May 4, 2017
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Rama K. Mishra, Leonidas C. Platanias, Javier Izquierdo-Ferrer
  • Patent number: 9597321
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: March 21, 2017
    Assignee: Angion Biomedica Corp.
    Inventors: Bijoy Panicker, Rama K. Mishra, Dong Sung Lim, Lambertus J. W. M. Oehlen, Dawoon Jung
  • Publication number: 20160152679
    Abstract: The present invention is directed to novel relaxin-like compounds having at least one intramolecular or intramolecular bridge that is a bioisosteric substitution of a cystine.
    Type: Application
    Filed: May 24, 2013
    Publication date: June 2, 2016
    Applicant: ANGION BIOMEDICA CORP.
    Inventors: Prakash Narayan, Rama K. Mishra, E. Siobhan McCormack, Victor M. Garsky, Itzhak D. Goldberg
  • Publication number: 20160060322
    Abstract: The present invention is directed to novel peptides that exhibit relaxin activity, and uses thereof for treating diseases such as heart failure and liver, lung, cardiac or kidney fibrosis.
    Type: Application
    Filed: September 10, 2013
    Publication date: March 3, 2016
    Applicant: ANGION BIOMEDICA CORP.
    Inventors: Parkash Narayan, Itzhak D. Goldberg, Rama K. Mishra, E. Siobhan McCormack, Dawoon Jung
  • Publication number: 20150306078
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
    Type: Application
    Filed: May 5, 2015
    Publication date: October 29, 2015
    Applicant: ANGION BIOMEDICA CORP.
    Inventors: Bijoy PANICKER, Rama K. MISHRA, Dong Sung LIM, Lambertus J.W.M. OEHLEN, Dawoon JUNG
  • Publication number: 20150158853
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.
    Type: Application
    Filed: September 23, 2014
    Publication date: June 11, 2015
    Applicant: ANGION BIOMEDICA CORP
    Inventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J.W.M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung